Hugo J.W.L. Aerts
Brigham and Women's Hospital
244 Papers
793 Citations
Hugo J.W.L. Aerts is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 62, co-authored 204 publications. Previous affiliations of Hugo J.W.L. Aerts include Harvard University & Stanford University.
Chat about Author
Papers
SU‐F‐R‐52: A Comparison of the Performance of Radiomic Features From Free Breathing and 4DCT Scans in Predicting Disease Recurrence in Lung Cancer SBRT Patients
E Huynh,Thibaud P. Coroller,Vivek Narayan,Vishesh Agrawal,J Romano,Idalid Franco,Y Hou,Raymond H. Mak,Hugo J.W.L. Aerts +8 more
TL;DR: The aim of the current study is to evaluate and compare the prognostic performance of radiomic features extracted from FB and AIP images in lung cancer patients treated with SBRT to identify which image type would generate an optimal predictive model for recurrence.
1
Cardiac Events after Radiation Therapy (RT) for Stage II-III Non-Small Cell Lung Cancer (NSCLC): Analysis of 748 Patients
Katelyn M. Atkins,Bhupendra Rawal,Christopher L. Williams,Danielle S. Bitterman,Tafadzwa L. Chaunzwa,Vishal Verma,David Kozono,Elizabeth H. Baldini,A.B. Chen,Anju Nohria,Hugo J.W.L. Aerts,Raymond H. Mak +11 more
1
Using virtual clinical trials to determine the accuracy of AI-based quantitative imaging biomarkers in oncology trials using standard-of-care CT
Darrin Byrd,Dennis Bontempi,Hao Yang,Hugo J.W.L. Aerts,Binsheng Zhao,Andriy Fedorov,Lawrence H. Schwartz,Tavis L. Allison,Chaya Moscowitz,Paul E. Kinahan +9 more
- 04 Apr 2022
TL;DR: The results indicate the feasibility of using VCTs to estimate the repeatability and reproducibility of AI-based biomarkers used in clinical trials with standard-of-care CT.
Low skeletal muscle area and association with toxicity and hospitalization with chemotherapy in advanced non–small cell lung cancer.
Anurag Saraf,J. He,Kee Young Shin,Jakob Weiss,Yu-Hui Chen,Paul J. Catalano,Mark M. Awad,David C. Christiani,Hugo J.W.L. Aerts,Raymond H. Mak +9 more
TL;DR: Low SMI predicted higher risk of G3+ toxicity during first cycle of chemotherapy, and high-risk patients with low SMI should be considered for more aggressive symptom management or alternative treatment strategies.